Related references
Note: Only part of the references are listed.Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease
Karen E. Murphy et al.
BRAIN (2014)
Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies
Jose Bras et al.
HUMAN MOLECULAR GENETICS (2014)
Neuroinflammation and α-synuclein accumulation in response to glucocerebrosidase deficiency are accompanied by synaptic dysfunction
Edward I. Ginns et al.
MOLECULAR GENETICS AND METABOLISM (2014)
Progressive myoclonus epilepsy: extraneuronal brown pigment deposition and system neurodegeneration in the brains of Japanese patients with novel SCARB2 mutations
Y. -J. Fu et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2014)
Mitochondria and Quality Control Defects in a Mouse Model of Gaucher Disease-Links to Parkinson's Disease
Laura D. Osellame et al.
CELL METABOLISM (2013)
Is Parkinson disease associated with lysosomal integral membrane protein type-2?: Challenges in interpreting association data
Emerson Maniwang et al.
MOLECULAR GENETICS AND METABOLISM (2013)
The role of SCARB2 as susceptibility factor in Parkinson's disease
Franziska Hopfner et al.
MOVEMENT DISORDERS (2013)
Structure of LIMP-2 provides functional insights with implications for SR-BI and CD36
Dante Neculai et al.
NATURE (2013)
The role of autophagy in neurodegenerative disease
Ralph A. Nixon
NATURE MEDICINE (2013)
Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies
S. Pablo Sardi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies
Karen E. Murphy et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2013)
Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains
Matthew E. Gegg et al.
ANNALS OF NEUROLOGY (2012)
PARK9-associated ATP13A2 localizes to intracellular acidic vesicles and regulates cation homeostasis and neuronal integrity
David Ramonet et al.
HUMAN MOLECULAR GENETICS (2012)
Deficiency of ATP13A2 Leads to Lysosomal Dysfunction, α-Synuclein Accumulation, and Neurotoxicity
Marija Usenovic et al.
JOURNAL OF NEUROSCIENCE (2012)
Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration
Benjamin Dehay et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
A Critical Histidine Residue Within LIMP-2 Mediates pH Sensitive Binding to Its Ligand β-Glucocerebrosidase
Christina Zachos et al.
TRAFFIC (2012)
Excess α-synuclein worsens disease in mice lacking ubiquitin carboxy-terminal hydrolase L1
Derya R. Shimshek et al.
SCIENTIFIC REPORTS (2012)
Gaucher Disease Glucocerebrosidase and α-Synuclein Form a Bidirectional Pathogenic Loop in Synucleinopathies
Joseph R. Mazzulli et al.
CELL (2011)
Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease
Suzanne Lesage et al.
HUMAN MOLECULAR GENETICS (2011)
A Mutation in SCARB2 is a Modifier in Gaucher Disease
Arash Velayati et al.
HUMAN MUTATION (2011)
α-Synuclein Interacts with Glucocerebrosidase Providing a Molecular Link between Parkinson and Gaucher Diseases
Thai Leong Yap et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Accumulation and distribution of α-synuclein and ubiquitin in the CNS of Gaucher disease mouse models
Y. H. Xu et al.
MOLECULAR GENETICS AND METABOLISM (2011)
Parkinson's Disease and α-Synuclein Expression
Michael J. Devine et al.
MOVEMENT DISORDERS (2011)
Neuropathology in Mice Expressing Mouse Alpha-Synuclein
Claus Rieker et al.
PLOS ONE (2011)
Exploring the link between glucocerebrosidase mutations and parkinsonism
Wendy Westbroek et al.
TRENDS IN MOLECULAR MEDICINE (2011)
Web-Based Genome-Wide Association Study Identifies Two Novel Loci and a Substantial Genetic Component for Parkinson's Disease
Chuong B. Do et al.
PLOS GENETICS (2011)
Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor-Rakeb syndrome
A. S. Al-Din et al.
ACTA NEUROLOGICA SCANDINAVICA (2010)
Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders
Ozlem Goker-Alpan et al.
ACTA NEUROPATHOLOGICA (2010)
Disease-causing mutations within the lysosomal integral membrane protein type 2 (LIMP-2) reveal the nature of binding to its ligand β-glucocerebrosidase
Judith Blanz et al.
HUMAN MOLECULAR GENETICS (2010)
Specific saposin C deficiency: CNS impairment and acid β-glucosidase effects in the mouse
Ying Sun et al.
HUMAN MOLECULAR GENETICS (2010)
Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits
Ying Sun et al.
HUMAN MOLECULAR GENETICS (2010)
Interaction between parkin and mutant glucocerebrosidase variants: a possible link between Parkinson disease and Gaucher disease
Idit Ron et al.
HUMAN MOLECULAR GENETICS (2010)
Ultrasensitive in situ visualization of active glucocerebrosidase molecules
Martin D. Witte et al.
NATURE CHEMICAL BIOLOGY (2010)
Alpha-synuclein deficient mice are resistant to toxin-induced multiple system atrophy
Kiren Ubhi et al.
NEUROREPORT (2010)
SCARB2 Mutations in Progressive Myoclonus Epilepsy (PME) Without Renal Failure
L. M. Dibbens et al.
ANNALS OF NEUROLOGY (2009)
Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: A biological link between Gaucher disease and parkinsonism
Amy B. Manning-Bog et al.
NEUROTOXICOLOGY (2009)
Array-based gene discovery with three unrelated subjects shows SCARB2/LIMP-2 deficiency causes myoclonus epilepsy and glomerulosclerosis
Samuel E. Berkovic et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2008)
Cathepsin D is the main lysosomal enzyme involved in the degradation of α-synuclein and generation of its carboxy-terminally truncated species
Daniel Sevlever et al.
BIOCHEMISTRY (2008)
Reversal of peripheral and central neural storage and ataxia after recombinant enzyme replacement therapy in α-mannosidosis mice
Judith Blanz et al.
HUMAN MOLECULAR GENETICS (2008)
A nonsense mutation in the LIMP-2 gene associated with progressive myoclonic epilepsy and nephrotic syndrome
Andrea Balreira et al.
HUMAN MOLECULAR GENETICS (2008)
LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of β-Glucocerebrosidase
David Reczek et al.
CELL (2007)
Aggregated α-synuclein mediates dopaminergic neurotoxicity in vivo
Magali Periquet et al.
JOURNAL OF NEUROSCIENCE (2007)
Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase
Alfredo Ramirez et al.
NATURE GENETICS (2006)
Mice lacking α-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration
RE Drolet et al.
NEUROTOXICOLOGY (2004)
Neuropathology provides clues to the pathophysiology of Gaucher disease
KD Wong et al.
MOLECULAR GENETICS AND METABOLISM (2004)
LIMP-2/LGP85 deficiency causes ureteric pelvic junction obstruction, deafness and peripheral neuropathy in mice
AC Gamp et al.
HUMAN MOLECULAR GENETICS (2003)
Human α-synuclein-harboring familial Parkinson's disease-linked Ala-53→Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice
MK Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Neuronal α-synucleinopathy with severe movement disorder in mice expressing A53T human α-synuclein
BI Giasson et al.
NEURON (2002)
Deletion of the alpha-synuclein locus in a subpopulation of C57BL/6J inbred mice
Christian G. Specht et al.
BMC NEUROSCIENCE (2001)
Share Paper
